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Abstract 
Introduction: Cancer is a leading cause of death worldwide and it is estimated that deaths 
from this disease will rise to over 11 million in 2030. Most cases of cancer can be cured 
with surgery, radiotherapy or chemotherapy if they are detected at an early stage. 
However, current cancer therapies are commonly associated with undesirable side effects, 
as most chemotherapy treatments are cytotoxic and present poor tumor targeting.  
Areas covered: Lipid nanoparticles (LN) are one of the most promising options in this 
field. LN are made up of biodegradable generally recognized as safe (GRAS) lipids, their 
formulation includes different techniques, and most are easily scalable to industrial 
manufacture. LN overcome the limitations imposed by the need for intravenous 
administration, as they are mainly absorbed via the lymphatic system when they are 
administered orally, which improves drug bioavailability. Furthermore, depending on their 
composition, LN present the ability to cross the blood brain barrier, thus opening up the 
possibility of targeting brain tumors.  
Expert opinion: The drawbacks of chemotherapeutic agents make it necessary to invest in 
research to find safer and more effective therapies. Nanotechnology has opened the door 
to new therapeutic options through the design of formulations that include a wide range of 
materials and formulations at the nanometer range, which improve drug efficacy through 
direct or indirect tumor targeting, increased bioavailability and diminished toxicity.  
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1. Introduction  
According to the World Health Organization [1], cancer is one of the leading causes of 
death worldwide, and cancer deaths are projected to continue rising to over 13.1 million in 
2030. The main types of cancer are: lung, stomach, liver, colorectal, breast and cervical 
cancer; nevertheless, it can affect any part of the body and people of any age. Early 
detection of this disease through screening prevents the cancer from spreading to other 
parts of the body (metastasization) and thus improves survival rates. Cancer treatment 
frequently comprises a combination of surgery, radiotherapy and chemotherapy. Cure 
rates of surgically removable primary tumors that have not spread to other parts of the 
body are high (e.g. breast, colorectal). However, even when complete resection of the 
tumor is possible, chemotherapy is generally required.  
Chemotherapy has been used for more than 70 years, since mustard gas was used for the 
first time in the treatment of lymphomas [2], but it still presents severe side effects and 
limited efficacy. Most chemotherapeutic drugs act through interaction with DNA that 
causes irreparable damage or by impeding cell division, which finally leads to cell 
apoptosis. Chemotherapeutic drugs are generally classified as: alkylating agents 
(platinums, nitrogen mustard derivates, oxazophosphorines), anti-metabolites (pyrimidine 
analogues, anti-folates), mitotic inhibitors (vinka alkaloids, taxanes), topoisomerase 
inhibitors (topoisomerase-I inhibitors, topoisomerase-II inhibitors) and antitumor 
antibiotics (anthracyclines, bleomycin, mitoxantrone). Even if these drugs present efficacy 
against the disease, multi drug resistance (MDR) to chemotherapeutic agents complicates 
cancer treatment. This mechanism is mainly related to P-glycoprotein (P-gp), which 
extrudes the drug from the cell, decreasing the intracellular drug concentration and thus 
inhibiting its antitumor action. The group of alkyl lysophospholipids, which are non-DNA 
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affecting molecules, comprises another class of antitumor agents. Edelfosine, the 
prototype of these new drugs discovered in the late 1980s, presents several advantages 
over conventional antitumor drugs. It is a drug that can be administered orally, it acts 
selectively in tumor cells sparing healthy tissues and its mechanism of action is not based 
on DNA targeting but membrane triggered apoptosis [3]. Chemotherapy is mainly 
administered intravenously, a route which is generally associated with poor patient well-
being and compliance, and high clinical cost [4]. Moreover, it is also associated with a 
wide variety of severe side effects (mainly due to the poor targeting of cancer cells) such 
as myelosupression, gastrointestinal toxicity, alopecia, neuropathy, infertility or cardiac 
ischemia, among others. Bearing in mind all the drawbacks of chemotherapy, researchers 
are still investigating into new drugs and new delivery systems to obtain safer and more 
effective therapies that allow oral administration. 
Among drug delivery systems, lipid nanoparticles (LN) are promising drug carriers due to 
their effectiveness in targeting tumor tissue. They provide higher drug efficacy, as a result 
of an increased concentration of drug in tumor cells, and lower side effects [5]. LN can be 
divided into solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC) and lipid 
drug conjugates (LDC). In general, they can be defined as nanometer sized solid particles 
made up of biodegradable generally recognized as safe (GRAS) lipids. Besides the above-
mentioned advantages, LN can be administered orally, avoiding all the disadvantages of 
the intravenous route. Like other nanosystems, LN are passively targeted to the tumor 
tissue due to the well-known enhanced permeability and retention effect (EPR effect) [6, 
7]. Moreover, when given orally, they are absorbed via the lymphatic system avoiding first 
pass hepatic metabolism and targeting lymph nodes [8, 9]. Depending on their 
composition, they also have the ability to cross the blood brain barrier (BBB), thus 
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opening up the possibility of targeting brain tumors [10]. Furthermore, active targeting 
offers the possibility of directing the drug toward different tissues. This review focuses on 
the most recent advances in the use of LN in the treatment of cancer. Specifically, studies 
published in the last 5 years will be reviewed and discussed. 
 
2. Lipid Based Nanosystems  
The LN concept begins with lipid nanosuspensions. O/W emulsions were first used in 
clinic in the 1950s to administer parenteral nutrition. Afterwards, Etomidat-Lipuro
®
 and 
Diazepam-Lipuro
®
 were successfully marketed [11]. At this time, the only purpose of 
these emulsions was to reduce the side effect of pain after diazepam injection. Despite the 
success of the O/W emulsions, the number of products on the market is low due to their 
physical instability and low drug solubility.  
Lipid based nanosystems were first launched on the market in 1986 by the Dior brand 
[12]. The Dior commercial formula was followed by the first pharmaceutical liposome 
formulations. Epi-Pevaryl
®
 (antimycotic topical therapy) was introduced in the market in 
the 1980s, and Alveofact
®
 (pulmonary instillation) and Ambisome
®
 (intravenous 
injection) in the following decade. One of the major disadvantages of liposomes is their 
rapid plasma clearance. Consequently, pegylated liposomes (stealth liposomes) were 
developed by Allen et al. in 1994 [13] as a solution to the short half-life of liposomes in 
plasma as a result of the reticuloendothelial system (RES) clearance. However, the number 
of commercialized liposomal formulations is low due to disadvantages such as physical 
instability, insufficient drug solubility and the need for expensive technology. Besides, 
regardless of the potentiality of these formulations in reducing drug-side effects, their poor 
controlled release posed a challenging drawback.  
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In this sense, LN, invented in the 1980s, represent significant progress in the development 
of lipid based nanosystems.  
2.1 Types of lipid Based Nanosystems 
2.1.1 Solid Lipid Nanoparticles  
SLN were discovered by Speiser et al. in the 1980s when they formulated SLN by spray 
drying and nanopellets for peroral administration for the first time [14, 15]. SLN are 
colloidal carriers composed of lipids that are solid at body temperature. The use of solid 
lipids prevents the drug from immediate release. The drug is included in a solid matrix that 
makes the diffusion of the drug to the surface difficult. In addition, the lipids used to form 
SLN provide low acute and chronic toxicity [5]. In the 1990s, SLN were further developed 
by Müller et al. using high-pressure homogenization (HPH) methods [16, 17] and by 
Gasco et al., who used a warm microemulsion technique [18, 19]. The most important 
advantages of SLN over liposomes are controlled drug release and the physical stability of 
the preparations. Nevertheless, they still present some limitations such as limited drug 
loading and drug expulsion during storage. Anticancer drugs have been encapsulated into 
SLN by many different authors [5]. Most of these studies have developed SLN to be 
administered intravenously, with successful results; nevertheless, SLN can also be a very 
promising oral drug delivery system. Several studies have demonstrated that these 
nanocarriers are absorbed via the lymphatic system, improving drug bioavailability [8, 9, 
20]. Consequently, the oral administration of antitumor agents might have a large impact 
on clinical practice both in patient well-being and in treatment costs [4]. 
2.1.2 Nanostructured Lipid Carriers  
NLC are the second generation of LN. They were developed by Müller et al. to solve the 
low drug loading capacity of SLN [21]. The difference between the two formulations is 
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their lipid composition: in NLC the solid lipid is mixed with a liquid lipid in order to 
obtain a solid structure and to avoid crystallization after particle solidification The 
applications of NLC are the same as Müller et al. described for SLN [17]. Several recent 
studies endorse the efficacy of NLC in cancer treatment [22-26].  
2.1.3 Lipid Drug Conjugates  
Although SLN and NLC are able to incorporate hydrophilic drugs, their lipophilic nature 
makes them more suitable to incorporate lipophilic compounds. LDC were developed in 
the late 1990s in order to achieve better drug loading rates for hydrophilic drugs [27]. 
Their manufacture consists of binding the drug to the lipid prior to forming the O/W 
emulsion. The drug is first conjugated with the lipid by salt formation or by covalent 
linkage, and afterwards, LDC are formed by homogenizing the drug-lipid complex with a 
surfactant aqueous solution by HPH.  
 
2.2. Preparation Methods 
To date, different methods have been developed to produce LN. Most of them are based 
on traditional emulsion techniques. The two principal methods used are the HPH, patented 
by Müller and Lucks in 1993 [17], and microemulsion techniques patented by Gasco in 
1993 [19]. However, several variations of these methods have been proposed in order to 
optimize the characteristics of LN formulations. Table I brings together all these methods 
and variations along with the drugs used in cancer therapy that have been successfully 
loaded in these systems. Research efforts have been focused on the improvement of 
particle stability, surfactants at considerable concentration, particle size control according 
to the administration routes, functionalization of the particle surface for targeting a 
specific cell, drug controlled release, minimal mechanical and thermal energy input, risk 
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of organic solvent residues, cost-effective process and industrial scalability, among others. 
The main advantages and drawbacks of all the production techniques are summarized in 
Table II. 
 
3. Scaling-up of LN  
After the development and optimization of a formulation on a small scale, the next step is 
usually to find the way to produce it on a larger scale. However, in most cases, the scaling 
up of a process implies an increase in problems [28]. In the case of LN production based 
on HPH, which is the most widely used method in the pharmaceutical industry, it has been 
observed that the use of larger scale machines leads to an even better quality of the 
product with regard to a smaller mean particle size and polydispersity index (PDI) [29]. 
The most typical devices for lab-scale production are the Avestin C5 (capacity: 5 L/h, 
batch: 7 mL to 1 L, Avestin Europe) and the Micron LAB 40 (batch: 20–40 mL, APV 
Deutschland GmbH). In the case of very high-cost drugs, or if there is a limited amount 
available (e.g., new chemical entities), it is positive to reduce the batch size. Avestin B3 
(Avestin Europe) can be employed in order to reduce the batch size, achieving a final 
volume of 0.5–3.2 mL [30].  
The next scaling up step implies a minimum batch size of 2 kg and a maximum of 10 kg. 
This aim can be achieved using the Micron LAB 60 (APV Deutschland GmbH), which has 
a homogenization capacity of 60 L/h. The next step in scale-up is the use of a Gaulin 5.5 
(APV Deutschland GmbH) with a homogenization capacity of 150 L/h (nearly 150 kg) 
[31]. In this case, the pre-emulsion is formed in larger containers. The product containers 
and homogenizer are manufactured from pharmaceutical grade materials. Another feature 
is that the product containers can be sterilized by autoclaving; formation of the pre-
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emulsion under protective gas is also feasible. It is noteworthy that a batch size of about 
500 kg can be produced in approximately 3-h homogenization time using this machine.  
For even larger scales, a Rannie 118 (APV Deutschland GmbH) or an Avestin EmulsiFlex 
C1000 (Avestin Europe) can be used [30, 31]. Their capacity is much higher than that of 
the previous machines, ranging from 1,000 to 2,000 L/h at the low pressure required for 
the production of LN.  
 
4. Physical-chemical characterization of LN 
Physical-chemical characterization of the LN is essential due to the fact that these systems 
present colloidal sized particles [32]. Nevertheless, proper characterization of the 
formulations is necessary to control the product quality, stability, and release kinetics. The 
most important parameters of LN to be characterized include particle size and shape, the 
surface charge, the degree of crystallization and the kind of lipid modification. All these 
properties must be well characterized because any contact of the LN dispersion with new 
surfaces might be able to induce changes in their structure, causing, for example, an 
alteration in the lipid crystallization or modification leading to the formation of a gel, or to 
the drug expulsion. Among all the parameters that should be considered for 
characterization of LN, size is crucial and critical for determining the interactions of 
nanoparticles with living systems. For instance, particle sizes below 300 nm are suitable 
for intestinal transport to the thoracic duct [33], while sizes no larger than 5 µm are 
required in order not to cause embolisms after parenteral administration of LN due to the 
blocking of the thin capillaries [34]. Besides, particle size also plays a very important role 
in the clearance of the LN by the RES. A great number of methods are available for 
determining the size of nanoparticles [35]; however, dynamic light scattering (DLS) is 
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generally used to determine the size distribution profile of LN. Alternatively, electron 
microscopy and/or atomic force microscopy (AFM) are often used to corroborate the 
results. 
The zeta potential is the overall charge a particle gains in a specific medium, and its value 
indicates the degree of repulsion between close and similarly charged particles in 
dispersion. Most authors calculate this value by laser-doppler anemometry [36, 37-40]. 
Colloids with high zeta potential (negative or positive) are electrically stabilized, while 
colloids with low zeta potentials tend to coagulate or flocculate. In general, absolute 
values greater than 30 mV have been found to be enough for good stabilization, and hence 
indicate good physical stability [41]. In terms of stability, any contact of the LN dispersion 
with new surfaces might be able to induce changes in their structure, causing, for example, 
an alteration in the lipid crystallization or modification leading to the formation of a gel or 
to the drug expulsion [42]. Therefore, the crystallinity and polymorphic behavior of the 
components of the LN should be studied, as these both influence drug incorporation and 
release rates to a high degree. Differential scanning calorimetry (DSC) and X-ray 
diffractometry (XRD) are two of the main tools employed. Bunjes and coworkers [43-46] 
report on crystalline properties of lipids and their recrystallization patterns during 
nanoparticle preparation and the influence of nanoparticle size on recrystallization pattern 
in a very extensive way.  
It is imperative to obtain a dry product to ensure their stability, thus allowing their long-
term storage. Lyophilization is one of the most widely used techniques for obtaining dry 
powders from nanoparticulate suspensions [47-51] and provides an increase in chemical 
and physical stability over extended periods of time [34]. In general, cryoprotectant agents 
are used so as not to achieve a final LN aggregated product, which will commonly acquire 
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a rubbery appearance. Saccharides are the most widely employed cryoprotectant agents in 
the formulation of LN, namely trehalose, sucrose, sorbitol, maltose, glucose and mannose 
[52-54].  
 
5. Drug release from LN 
The solubility of the drug in the aqueous release medium and the lipid component of the 
formulation, and the partitioning between them, are considered very important factors in 
predicting the in vitro drug release behavior. It is known that increasing the production 
temperature and surfactant concentration leads to increased drug solubility in the water 
phase [55]. Cooling the LN suspension again will decrease the water solubility and the 
repartition to the lipid, forming drug core-enriched or drug shell-enriched LN, depending 
on the lipid recrystallization temperature [56]. These two drug distribution models lead to 
too slow and too fast release rates of the drugs, respectively.  
In order to study the drug release kinetic profile of drugs from LN, various assays can be 
performed. The most widely employed assays are based on the use of dialysis membranes, 
Franz-type diffusion cells and rotating vials.  
5.1 Dialysis membranes 
Among all assays, dialysis tubes are the most widely used to study the drug release 
kinetics from LN formulations [53, 57-59]. Briefly, a definite amount of prepared LN, free 
from any unentrapped drug, is separately placed in the dialysis tube of different molecular 
weight cut-off (MWCO) (usually between 12-14 kDa), tied at both ends and suspended in 
different beakers (receptor compartment) each containing the appropriate medium to study 
the release (namely, PBS, gastric or intestinal media). The medium is stirred continuously 
to favor the crossing of the membrane, and the whole system is usually assembled at 
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physiologic temperature throughout the experiment (Figure 1). Samples are withdrawn 
periodically and after each withdrawal of sample the same volume of appropriate medium 
is added in the receptor compartment so as to maintain a constant volume throughout the 
study.  
5.2 Franz-type diffusion cell 
This assay is relatively similar to the method based on dialysis membranes, with the 
difference of the use of a specific system [60-52]. A Franz diffusion cell system is 
composed of a receptor and a donor cell (Figure 2). This cell has a static receptor solution 
reservoir with a side-arm sampling port. The membrane (usually of a MWCO of 12 kDa) 
is mounted between the cell compartments. The receptor compartment is filled with the 
appropriate medium to study the release (namely, PBS, gastric or intestinal media). It is 
kept at physiological temperature by circulating water through an external water jacket. 
After a certain time of equilibration of the membrane with the receptor solution, a definite 
amount of the LN formulation is applied in the donor compartment. The donor 
compartment can then be covered to prevent evaporation of the solvent. The receptor 
solution is continuously stirred by means of a spinning bar magnet. Receptor solution 
samples are withdrawn through the sampling port of the receptor compartment at various 
time intervals and the cells are refilled with receptor solution to keep the volume of 
receptor solution constant during the experiment.  
5.3 Rotating vials 
In this method, an amount of LN is placed in small vials contaning the appropriate 
medium to study the release (PBS, gastric or intestinal media). The vials undergo 
continuous rotational mixing using a rotating device kept at physiologic temperature 
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throughout the experiment (Figure 3). At the time of sample withdrawal, vials are 
centrifuged and the supernatant is recovered for analysis [36]. 
 
6. Application in cancer therapy 
6.1 Surface modified lipid based nanosystems 
Antitumor drugs imply many remarkable side effects as a result of their impaired toxicity. 
The poor selectivity of these compounds makes them accumulate in healthy tissues 
causing severe damage. This unspecific drug accumulation also decreases their 
effectiveness [2]. Nanotechnology has overcome this problem thanks to passive and active 
targeting of the tumor. Lipid-based nanocarriers are not only able to accumulate in tumor 
tissues passively, but these systems can also be actively targeted at tumors by attaching 
different molecules to their surface (Figure 4). 
6.1.1 Passive targeting 
The EPR effect is the principal mechanism of tumor accumulation of nanocarriers [7]. 
Tumor tissues grow very quickly, promoting special tissue architecture and the 
development of blood vessels with wide fenestrations between endothelial cells. These 
particular vessels permit an easier exchange of nutrients and oxygen to support the high 
demand of this abnormal growth. These wider spaces facilitate the extravasation and 
accumulation of nanoparticulated systems from the blood vessels into the tumor tissues. 
Therefore, lipid-based nanosystems are targeted at tumor tissues in a passive way, which is 
based on the shape and size and is independent of the surface nature.  
In contrast to other nanocarriers, LN offer another possibility in passive targeting when 
they are administered orally. After oral administration, LN are absorbed via the lymphatic 
system and the drug is passively targeted at the lymph nodes [20, 61]. This might represent 
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a promising strategy in the treatment of general cancer metastases and in lymph generated 
tumors (lymphomas) [9]. 
Another passive targeting approach is the use of certain tensoactive excipients that enable 
the lipid nanocarriers to penetrate into the central nervous system (CNS). Several studies 
suggest that LN including tensoactive excipients such as polysorbate 80 (Tween 80) or 
polyoxyethylene 20-stearyl ether (Brij 78) may overcome the BBB, allowing the drug to 
penetrate into the CNS [10, 62]. Taking into consideration the difficulties of anticancer 
drugs in crossing the BBB, LN present high potential as therapeutic tools against brain 
tumors. 
6.1.2 Active targeting 
Passive targeting is mainly used in nanotechnology to target nanocarriers at the tumor; 
nevertheless, many authors have developed active targeted LN. In this section we will 
discuss the main strategies developed to target LN to cancer cells. Efficacy studies will be 
described and documented in section 6.2. Active targeting consists of attaching molecules 
to the surface of the nanoparticle. The main strategy in active targeting consists of using 
ligands that specifically bind to molecules that are selective or over-expressed in tumor 
cells. However, other approaches like hepatic cell targeting [63] and magnetic targeting 
[64] are also common.  
Among all the molecules used for specific cancer cell targeting, transferrin (Tf) attachment 
is a widely used strategy [65-67]. Tf receptor is the ubiquitous cell surface glycoprotein 
related to cell proliferation and is over-expressed in malignant tissues because of the 
higher iron demand of malignant cells for fast growth and division [65]. Tf binds to its 
specific receptor on the cell surface and is internalized into the cell by endocytosis.  
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The attachment of ferritin to the nanoparticle surface is another approach related to the 
increased iron requirements of cancer cells. Ferritin is an intracellular protein complex, 
which is intended to store iron in the cell in a non-toxic form. Jain et al [68] developed 
ferritin-mediated LN containing 5-fluorouracil (5-FU) to assess their targetability to breast 
cancer cells. 
Mannose has been also used as a ligand in active targeting of lipid nanocarriers [69]. 
Cancer cells tend to over-express lectin-like receptors with high affinity for polysaccharide 
molecules on their surface. This occurs as a result of the increased requirement for 
carbohydrate molecules by tumor tissues. Mannosylated LN containing doxorubicin 
(DOX) showed enhanced in vitro and in vivo efficacy compared to non-targeted LN or 
free drug [58].  
Taking advantage of the cancer cell augmented metabolism, another targeted strategy 
developed is the use of hyaluronan (HA) of different molecular weights [70, 71]. HA is a 
linear glycosaminoglycan with many biological functions that make it essential in tumor 
development. HA can be covalently attached to the surface of LN to target epithelial 
cancer cells and leukocytes over-expressing HA receptors (CD44 and CD168). Mizrahy et 
al. [70] demonstrated that low molecular weight HA might be used as a secure substitute 
for polyethylene glycol (PEG) if macrophage or complement activation must be avoided. 
Previous studies demonstrated that low molecular weight HA (LMW-HA) but not high 
molecular weight HA (HMW-HA) induced inflammatory response [72]; however, 
Mizrahy et al. showed that macrophage activation avoidance was HA molecular weight 
independent. This could be explained by the low quantity of HA attached to the LN 
surface compared to preceding studies. Besides, HMW-HA may be used to efficiently 
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target CD44 over-expressing tumors due to the strong binding of HMW-HA to the 
receptor. 
Folate-mediated LN has also been developed to achieve active targeting [73, 74]. Folate 
receptor has been identified as a useful tumor marker because it is over-expressed in 
cancer cells. Folate is essential in eukaryotic cells for the biosynthesis of nucleotide bases 
and, as in the previous cases, its requirement is increased in cancer cells by reason of its 
accelerated metabolism.  
αvβ3 integrins are another target in nanocarrier design. These receptors are over-expressed 
in angiogenic vessels and in some cancer cells. In a study carried out by Goutayer et al. 
[75], NLC containing a fluorochrome were functionalized with cyclic triad peptide 
sequence RGD (Arg-Gly-Asp) in order to target αvβ3 integrins. Functionalized LN were 
shown to have a long half-life in plasma and were distributed widely except for the CNS. 
Fluorochrome signal was higher in tumor tissues over-expressing target receptors, 
indicating a targeted distribution of LN. 
Apart from this selective targeting of cancer cells, there is another strategy that consists of 
targeting a specific tissue such as liver or brain. In this sense, selective targeting to hepatic 
cells is another common approach in nanomedicine. Asialoglycoprotein (ASGP) receptor 
is commonly used as a therapeutic target in hepatic disease [63]. In contrast to the 
previous approaches, attaching a hepatic ligand implies targeting of all hepatic cells 
including healthy tissue. Nevertheless, the EPR effect may help to overcome this 
drawback, by promoting uptake of nanocarriers by tumor.  
CNS has also been targeted through the binding of ligands to the LN surface. Cationic 
bovine serum albumin (CBSA) promotes transport across the brain capillary endothelial 
cells [76, 77]. CBSA has recently been used to target LN of DOX to the CNS [78]. In this 
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case, ligand attachment delays in vitro drug release from the nanoparticle. Moreover, 
CBSA-mediated LN were uptaken by cells in a higher rate.  
LN can be also targeted through physical approaches using magnetic fields [64]. Besides, 
drug release from magnetic LN can be controlled when nanoparticles are exposed to an 
alternating magnetic field [79]. 
Summarizing, all these possibilities of targeting lead to the conclusion that, although 
passive targeting has clearly increased antitumor drug efficacy, active targeting clearly 
improves drug efficacy and security. In fact, active targeting of lipid nanocarriers might be 
considered an added improvement of passive targeting. LN accumulate in tumor tissue not 
only due to their physical characteristics but also because of specific binding to cancer 
cells.  
6.2 Cancer therapy using LN  
This review is intended to discuss the treatment of cancer with lipid nanocarriers focusing 
on the past five years. Tumor extirpation combined with radiotherapy, chemotherapy and 
monoclonal antibodies are conventional treatments in early stages of the disease. 
However, these therapies are not always effective and entail severe side effects. For this 
reason, new therapeutic strategies are being investigated. Among all these possibilities, 
LN are promising drug delivery systems due to the possibility of selectively targeting the 
nanoparticles at tumor tissues, providing effective and secure therapies. 
6.2.1 Lung cancer 
Lung cancer is the leading cause of cancer death in the world. This high mortality rates are 
mainly caused by a late diagnosis of the disease that is associated with non-operable 
stages. Non-small cell lung cancer (NSCLC) is the most common lung cancer type [80]. 
NSCLC is composed of heterogeneous aggregates of histologies that include epidermoid 
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or squamous cell carcinoma, adenocarcinoma and large cell carcinoma. Despite 
improvements in NSCLC therapy, the overall survival at 5 years depends on the cancer 
stage at diagnosis varying from 49% or 16% to 2% for patients with local, regional, and 
distant stage, respectively. NSCLC responds badly to radiotherapy and chemotherapy, so 
patients are frequently included in clinical trials [81]. With this basis in mind, novel 
formulations are being developed in order to obtain more secure therapies.  
In the last five years, different authors have incorporated antitumor drugs into lipid 
nanocarriers to treat lung cancer [52, 82, 83]. These studies show that lipid vehicles 
protect labile drugs from degradation, increase drug bioavailability, enhance drug tumor 
uptake and decrease toxicity. Wan et al [83] studied the in vitro efficacy of pegylated-LN 
containing vinorelbine bitartrate (VB) in A-549 cancer cells. VB is a semi-synthetic vinca 
alkaloid currently registered for the treatment of NSCLC in many countries. It is a very 
labile and hydrophilic drug that possesses rapid clearance [84]. Pegylation, coupling of 
PEG to the surface of the nanocarriers, is a common strategy to avoid macrophage uptake 
and subsequent LN clearance by the reticuloendothelial system (RES) [85]. Pegylated-LN 
containing VB were able to reduce macrophage cell uptake by RAW264.7 cells because of 
PEG coupling on their surface; furthermore, they were internalized in a higher rate than 
the free drug in A-549 lung tumor cells. These results might increase in vivo efficacy of 
VB. Another study carried out by Jain et al. [58] was based on the use of LN to 
encapsulate DOX, which is a cytostatic antibiotic with a narrow therapeutic index and 
severe cardiac toxicity. These authors developed a mannosylated LN formulation of DOX, 
which was tested in vitro in A-549 cells. The hemolytic effect of DOX was avoided when 
it was encapsulated into LN. In vivo studies in male BALB/c mice showed that 
intravenously administered LN increased biodisponibility of DOX, which is cleared from 
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plasma very quickly when it is administered in its free form. Moreover, vehiculized DOX 
accumulated in tumor tissue (xenograft A-549) at a higher rate than the free drug, avoiding 
toxicity in healthy cells.  
Gene therapy has also been combined with lipid nanosystems in the treatment of lung 
cancer. Shi et al. [82] investigated the effect of encapsulating anti-microRNA 
oligonucleotides (AMOs) for suppression of microRNA-21 (miR-21) functions in human 
lung cancer cells. A-549 human cancer cell line presents over-expression of miR-21, 
which causes cell proliferation and inhibits apoptosis. These AMOs cannot be 
administered in their free form due to their labile nature, and therefore LN constitute a 
promising drug delivery system in gene therapy. The in vitro results of the study clearly 
indicate that AMOs transfection efficacy is enhanced when it is encapsulated into LDC. 
Besides, this is the first time that AMOs is encapsulated instead of complexed. The high 
rate of transfection in A-549 cells inhibited cell proliferation and promoted apoptosis; 
moreover, cell motility was also inhibited. 
6.2.2 Colon cancer 
Colon cancer is one of the most common cancers worldwide. The prognosis of the disease 
is directly related to the penetration of the cancer through the bowel wall. Bowel localized 
cancer is removed by surgery and is curable in only 50% of the cases because recurrence 
is very frequent. Moreover, as in most cancer types, tumors are detected at an advanced 
stage and so radiotherapy and chemotherapy are the only feasible treatments [86]. 
Antitumor drugs against colon cancer have been encapsulated into LN by several authors 
lately [87, 88]. 5-FU is an antimetabolite widely used in colorectal cancer treatment but it 
presents large individual variability in pharmacokinetics and its toxicity is closely related 
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to this variability. Yassin et al. [87] incorporated this drug into LN successfully; however, 
they did not test the efficacy of the formulation either in vitro or in vivo.  
6.2.3 Breast cancer 
Breast cancer is the second leading cause of cancer death in women after lung cancer. It 
causes death in about 3% of the cases. The decline in death rates since 1990 is mainly a 
result of early detection programs. These preventive measures have allowed the complete 
elimination of most tumors by surgical resection. This measure is commonly associated 
with local radiotherapy, systemic chemotherapy, hormone therapy or targeted therapy 
[89].  
Many drugs have been vehiculized through lipid nanocarriers to achieve better drug 
efficacy and decrease toxicity in breast cancer treatment [58, 65, 68, 75, 83, 90-94].   
Capecitabine is a prodrug of 5-FU that must be converted by enzymes that are mainly 
restricted to the liver and tumor site. In this sense, capecitabine and its analogues have 
fewer side effects than 5-FU; nevertheless, its rapid plasma clearance requires frequent 
dose regimens. LN are a promising tool due to their ability to provide controlled drug 
release and, subsequently, improved dose regimens. Capecitabine analog (5-FCPal) was 
encapsulated by Gong et al. in LN [93]. The in vitro results in MCF-7 breast cancer cells 
showed that encapsulated 5-FCPal was as effective as capecitabine and less toxic than 5-
FU. In vivo study on a mouse breast cancer model in female BALB/c mice did not show 
any significant differences between free capecitabine and encapsulated 5-FCPal analog 
administered via orogastric gavage; however, a tendency to higher efficacy was observed 
in the LN group. The authors also postulate that LN containing 5-FCPal might be 
administered on an intermittent basis obtaining similar efficacy due to controlled drug 
 22 
release. More studies are required in order to demonstrate that LN administered 
intermittently could provide similar efficacy to the free drug administered daily.  
Lu et al. [90] encapsulated the antitumor drug mitoxantrone (MTO) in LN. Heart toxicity, 
myelosupression and local toxicity at injection site are reported frequently when using this 
drug against breast cancer. Authors efficiently overcame these drug drawbacks by using 
LN to vehiculize the drug. A breast cancer model in BALB/c-nu nude mice was 
established and MTO-LN were subcutaneously injected. Not only were LN containing 
MTO more effective in restricting the action of the drug to the tumor site, but additionally, 
they were also able to avoid macrophage uptake by using the PEG derivated surfactant S-
40. Local injection of MTO-LN avoided hepatonecrosis and interstitial pneumonia that is 
caused by the free drug. The breast tumor model was not satisfactory in all animals and, 
therefore statistically significant results were not obtained. Preliminary histopathological 
results showed more necrotic areas and thinner overgrown tumor layer when mice were 
treated with the encapsulated drug. 
Wan et al. [83] evaluated the in vitro efficacy of including the antitumor drug VB in LN. 
As in the preceding study, these authors also aimed to protect LN from macrophage 
uptake, and so they decided to cover the LN surface with PEG. The increment in PEG 
percentage on the surface of the LN increases its hydrophilicity, thus avoiding macrophage 
uptake. In vitro efficacy in MCF-7 cells of nanoencapsulated VB was enhanced about 6.5 
fold compared to the free drug.  
Another approach in breast cancer therapy is the use of hormonal therapy. Most breast 
cancers need estrogen to grow, and estrogen-receptor antagonists are therefore used to 
block the receptor and hamper cancer development. Tamoxifen citrate (TC) is a 
nonsteroidal estrogen antagonist commonly used after mastectomy or in early breast 
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cancer stages. One study from Reddy et al. [91] incorporated TC in LN to evaluate the in 
vivo pharmacokinetics of the encapsulated drug in rats. They showed that 
nanoencapsulation of the drug produced higher plasma concentrations of TC and slower 
clearance, thus demonstrating again the potential use of LN as a secure and efficient drug 
delivery system in breast cancer. 
Tumor targeting improvement through functionalized LN has been demonstrated in a wide 
variety of studies. In the last few years, many studies have focused on the treatment of 
breast cancer with lipid nanocarriers possessing active targeting. Goutayer et al. [75] 
investigated the in vivo distribution of LN and the effect of functionalizing them in their 
biodistribution. They targeted the nanoparticles to αvβ3 integrins, over-expressed on 
angiogenic vessels and tumor tissues, achieving longer nanoparticle plasma circulation 
time. Nanoparticles were accumulated mainly in tumor tissue followed by uterus, ovarian 
and adrenal glands. Tumor targeting was achieved in the case of a cell line over-
expressing the target: in this case, functionalized nanoparticles accumulate in tumor tissue 
in a higher rate than non-targeted LN. Another study conducted by Jain et al. [58], in 
which LN were labeled with mannose, affirmed that functionalized lipid nanocarriers are 
more effective than free drug in inhibiting proliferation in breast cancer cells. Besides, in 
vivo bioavailability and tumor accumulation were enhanced when using LN, especially 
when they were coupled with mannose. Tf mediated LN has also been utilized to target 
antitumor drugs at breast cancer cells [65]. In this study, curcumin efficacy in MCF-7 cells 
was enhanced due to the use of functionalized nanoparticles. Curcumin is a physically 
labile antitumor drug that presents a low bioavailability profile. LN were effective in 
protecting the drug from degradation. Non-targeted LN were also effective but at a lower 
rate than Tf mediated LN. 
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5-FU is one of the most commonly used drugs in the treatment of breast cancer due to its 
effectiveness against several solid tumors; however, it presents serious drawbacks due to a 
lack of specificity for tumor cells [95]. Jain et al. [68] studied the possible advantages of 
using LN to target the drug towards the tumor tissue while avoiding its toxic effects. This 
also included the targeting of the LN with ferritin. In vitro results demonstrated that 
ferritin mediated LN containing 5-FU were internalized at a significant rate by breast 
cancer cells (MDA-MB-468) through a saturable mechanism. Furthermore, drug half-life 
in plasma was significantly enhanced when the drug was encapsulated in nanoparticles. 5-
FU accumulates in the tumor 7.7 times more than drug included in non-targeted LN or free 
drug.  
6.2.4 Brain cancer 
Nowadays brain diseases remain one of the most challenging pathologies to treat. Many 
circumstances make treatment of cerebral tumors particularly complicated. They are in 
many cases inoperable due to their location, and the BBB prevents drugs from crossing 
into the brain. BBB consists of physical (tight junctions) and metabolic (enzymes) 
barriers, which hamper the passing of drugs and toxins from circulation blood to the 
extracellular fluid of the brain. Lastly, the broad heterogeneity of brain malignancies 
makes the individual response to the treatment very unpredictable. Brain tumors are 
associated with high mortality rates despite their low incidence compared to other tumors. 
The pharmacology of brain cancer is always difficult but LN have provided a new insight 
in its treatment alternatives [10, 59, 78, 96-98].  
Several active and passive strategies have been used to enhance targeting of LN at the 
CNS. The inclusion of certain tensioactive agents has been demonstrated to be an 
effectively passive targeting strategy to bypass the BBB. Tensioactives such as Tween 80 
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enhance the binding of plasma proteins, with specificity for the BBB, to the LN surface 
[99]. Moreover, Tween 80 temporarily inhibits the MDR effect mediated by P-gp protein 
avoiding drug efflux [10]. Estella-Hermoso de Mendoza et al. investigated the in vitro 
efficacy and in vivo biodistribution of edelfosine-LN. Edelfosine is an antitumor drug with 
in vitro activity against several cancer cells [5, 10, 100, 101]. This study demonstrated that 
LN are able to inhibit P-gp in vitro and that they can thus revert the C6 cell line resistance 
to the free drug. Moreover, biodistribution studies showed drug accumulation in brain 
tissue after oral administration of the nanoencapsulated drug.  
Active targeting to the brain was also carried out by Agarwal et al. [78]. In this study they 
conjugated DOX LN with CBSA. They based their strategy on previous studies that 
demonstrated that CBSA promotes transport of nanoparticles across the BBB [76, 77]. The 
results of the study showed that CBSA conjugated LN provided slower drug release rates 
than empty-LN; this effect is commonly seen in lipid nanocarriers with attached ligands on 
their surface, which might happen because these added molecules act as extra barriers. 
Drug targeting was successfully achieved in vitro and in vivo through intravenous 
administration. CBSA conjugated-LN were able to target DOX to the CNS improving its 
brain concentration and avoiding side effects in healthy tissues. Kuo and Liang [59, 97] 
also applied active targeting attaching anti-EGFR to the nanoparticle surface, and since 
EGFR is normally expressed in glioma, the attachment of an antibody against this receptor 
can certainly improve drug efficacy. These authors have published two studies in which 
they encapsulate DOX and carmustine into EGFR-targeted LN. Both studies evaluated the 
in vitro efficacy on U87MG cells, and showed that the efficacy of chemotherapy was 
enhanced as a result of the EGFR targeting. 
6.2.5 Ovarian cancer 
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According to the American Cancer Society [102], ovarian cancer accounts for about 3% of 
all cancers in women and causes more deaths than any other cancer of the female 
reproductive system. It mainly affects older women, half of the diagnosed women being 
older than 60 years. As in other tumors, surgical removal of the tumor is the first option. 
Nevertheless, chemotherapy and radiotherapy must be administered in many cases if the 
main tumor cannot be removed or it has metastasized to other parts of the body. 
Chemotherapy in ovarian cancer is usually administered in combination therapy using a 
platinum compound, such as cisplatin or carboplatin, and a taxane, such as paclitaxel 
(Taxol
®
) or docetaxel (Taxotere
®
). Encapsulating, for example, docetaxel, into LN 
increased their efficacy compared to the commercial formulation (Taxotere
®
) [92]. 
Many researchers are investigating new drug delivery systems that may overcome MDR to 
common chemotherapy drugs. Among these new strategies, LN have been successfully 
evaluated in ovarian cancer [62, 70, 92, 103-105].  
As we have seen before, MDR can be overcome by using LN that include specific 
surfactants in their formulation. On this basis, one study developed by Dong et al. [62] 
confirmed that Brij 78 can also inhibit P-gp efflux pump and, consequently, increase not 
only drug internalization but also drug retention inside the cells. The study, which consists 
of LN containing DOX and paclitaxel, showed that both, blank-LN and LN containing the 
antitumor drugs were able to inhibit the P-gp mechanism in P-gp over-expressing human 
ovarian carcinoma cell line NCI/ADR-RES. This inhibition is followed by a transitory 
ATP depletion, which induces mitochondria stress and swelling as a desperate mechanism 
to obtain energy and supply ATP depletion. This study proves that LN containing certain 
tensioactive agents have an effect on the MDR mechanism that helps to achieve higher 
intracellular drug accumulation. In fact, the addition of free DOX after treating the cells 
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with non-loaded LN produced an in vitro cytotoxic effect similar to the drug loaded 
nanocarriers, probably due to the transitory P-gp inhibition.  
6.2.6 Hematological cancer 
Blood cancer includes leukemia, lymphoma and myeloma. Leukemia develops in the bone 
marrow and affects white blood cells; it has different subtypes depending on its speed of 
development and the subtype of white cells involved. Childhood leukemia is the most 
common cancer in children. Lymphoma is a blood cancer that appears as a solid tumor and 
is commonly located in the lymph nodes. It causes the production of abnormal 
lymphocytes. There are two types of lymphoma: non-Hodgkin (more common) and 
Hodgkin. Non-Hodgkin lymphoma is the most common blood cancer in teenagers and 
young people. Myeloma affects the plasma cells on the blood unbalancing the immune 
system. Myeloma mainly occurs in people over the age of 40.  
As has been mentioned before, lymphomas develop in lymph nodes, and so LN might be 
an appropriate tool to fight this cancer. Several studies support the theory that LN are 
absorbed by a lymphatic route after oral administration [8, 20, 61, 106]. LN can passively 
target lymph nodes by concentrating unmetabolized drug at the cancer origin. So far, the 
only study of orally administered LN to treat hematological cancers was performed by 
Estella-Hermoso de Mendoza et al [9]. In this work, very promising results were obtained 
after the oral administration of edelfosine loaded LN to mantle cell lymphoma bearing 
mice. These authors proved that the administration of drug loaded LN every four days was 
as effective as the daily free drug in decreasing tumor growth. Moreover, while the daily 
administration of the free drug was able to reduce the metastases by a half, the 
administration of drug loaded LN orally every four days completely eradicated the 
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metastatization process. This study offers new hopes in orally administered chemotherapy 
to treat this kind of cancer. 
In another study Reddy et al. [107] demonstrated that LN containing etoposide were more 
effective than the free drug after intraperitoneal administration in Dalton’s lymphoma 
ascites bearing mice. Controlled release of etoposide in this kind of intraperitoneal tumors 
is essential due to the necessity of prolonged exposure to the drug to obtain a cytotoxic 
effect. LN remains in the peritoneal cavity after intraperitoneal administration, providing 
sustained release of the drug and thus increasing its antitumor efficacy. Antitumor drug 
encapsulation into LN has been carried out by several authors for treating hematological 
tumors [9, 66, 108, 109]. Idarubicin and DOX were encapsulated into LN by Ma et al. 
[108] in order to avoid P-gp mediated MDR in leukemia patients and subsequent disease 
relapses. The results of the study showed that idarubicin inclusion into LN did not increase 
its efficacy. This could be explained because idarubicin uptake rate is much higher than its 
P-gp mediated efflux because of its lipophilic properties. DOX-LN were, in contrast, more 
effective than the free drug, probably due to the P-gp inhibition mechanism mediated by 
the surfactants (Brij 78 and Vitamin E TPGS) included in the formulation. 
Gene therapy has also been combined with LN in the treatment of leukemia leading to 
protection from serum nucleases, longer blood circulation and increased tumor 
concentration of oligodeoxyribonucleotides [109]. In addition, the coupling of these LN 
with Tf improves its targeting to leukemia cells over-expressing Tf-receptor. Moreover, 
targeting can be enhanced with a pretreatment with defeoxamine, a clinically used iron 
chelator which is known to up-regulate Tf-receptor expression in cells. 
6.2.7 Other cancer types 
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Many other studies have been performed in relation to other cancer types such as prostate, 
tongue, hepatocellular cancer, melanoma and sarcoma [57, 62, 63, 74, 92, 110-113]. In 
these studies, antitumor drugs and genetic material are encapsulated into LN.  
As in other approaches, genetic material is protected from plasma nuclease degradation 
and LN show higher in vitro transfection efficiency than commercially available gene 
carriers [110, 111]. Besides, an in vivo study carried out by Bauman et al. [110] with 
oligonucleotides that down-regulate Bcl-x (an anti-apoptotic member of the Bcl-2 family) 
demonstrated that they are able to induce splicing modification in tumor cells. 
Radiotherapy has also been combined with nanotechnology in the treatment of head and 
neck cancers. Some studies show that β-emitting radionuclides that are included in LN 
better accumulate and localize radiation in the tumor, sparing healthy tissues after 
intratumor administration [112]. 
LN are also a good strategy for topical oral delivery of poorly water soluble drugs used in 
oral cancer chemoprevention strategy [113]. Moreover, LN can reach connective tissue 
and, therefore, they could be used for systemic therapeutics through the oral mucosa. It is 
remarkable that this study also showed that LN must be in a high concentration in the 
treatment site to avoid MDR efflux; at a low concentration they conjugate with glutathione 
and are effluxed by cell proteins.  
The taxanes, including paclitaxel and docetaxel, have broad activity and are extensively 
used in clinical practice in the treatment of cancer. As explained before, several authors 
have vehiculized them into LN to treat ovarian and colorectal cancer; however, prostate, 
hepatocellular or sarcoma, among others, have also been investigated [57, 62, 63, 92]. As 
major antitumor drugs, taxanes comprise severe side effects because of their poor targeting 
and high toxicity; moreover, they exhibit poor water solubility. The studies mentioned 
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above demonstrated that, in all cases, encapsulated drug effects were more potent and 
toxic effects were avoided due to a lower accumulation in healthy tissues.  
 
7. Biodegradation, safety and toxicity aspects 
Over the past years, the development of lipid drug delivery systems has entailed a wide 
range of tasks such as the development of nanosystems that are suitable to specific 
applications, the type of release kinetics (pulsatile, fast, slow) and proof of efficacy. 
Furthermore, it is very important to prove the systems’ safety, which implies at least two 
major entities: the biocompatibility of the delivery system and the safety of the 
systemically distributed drug [114]. The control of the systemic drug distribution can be a 
relatively simple matter of engineering release kinetics so that blood levels are lower. 
Being in the solid state, the lipid components of LN will be degraded more slowly 
providing a longer lasting exposure to the immune system. Degradation can be slowed 
down even more when using sterically stabilizing surfactants that hinder the anchoring of 
enzyme complexes. Reducing biocompatibility problems can be much harder, involving 
drug-tissue interactions and material properties that are still not well understood. However, 
LN are biocompatible and biodegradable and have been used for controlled drug delivery 
and specific targeting. Furthermore, in terms of safety issues, one clear advantage of the 
use of LN as drug carrier systems is the fact that the matrix is composed of physiological 
components, that is, excipients with GRAS status for oral, topical and intravenous 
administration [5, 29, 101, 115, 116], which decreases the possible cytotoxicity. LN have 
been already tested as site-specific carriers mainly for drugs that present a relatively fast 
metabolism and are quickly cleared from the blood, that is, peptides and proteins [117, 
119]. LN are generally well tolerated, and as stated above they are mainly formulated 
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using biocompatible or physiological compounds that can be included in different 
metabolic pathways after degradation [120, 121].  
The biodegradation velocity of nanoparticles affects their toxicological acceptance (e.g. 
concentration of degradation products). As a result, many studies have been focused on the 
toxicology of LN, including genotoxicity and cytotoxicity studies [122]. It was observed 
that these effects usually occur at rather high concentrations, but the effects that happen at 
lower concentrations, without necessarily causing cell death, also should be taken into 
consideration.  
 
8. Concluding remarks  
LN have been shown to be effective carriers in cancer. The inclusion of anticancer drugs 
in LN improves drug efficacy and decreases side effects. Among all the advantages that 
these carriers offer, it is noteworthy that they protect labile drugs from degradation or 
rapid RES clearance. This is particularly relevant in the case of gene therapy or in 
antitumor drugs that have short plasma half-lives. Besides, they not only decrease toxicity 
but they also generally provide longer circulation times and higher concentration of the 
drug in tumor tissue. This proved efficacy is mainly based on passive and active targeting. 
Apart from these general considerations, LN present some particularly relevant 
advantages. First of all, they can be administered orally avoiding the tedious intravenous 
route in chemotherapy. When administered by this route, they are mainly absorbed via the 
lymphatic system, thus opening a new window in treatment of cancer metastases and 
lymphomas. Secondly, they can be targeted to the brain due to its capacity to cross the 
BBB when specific tensioactive compounds (Tween 80, Brij 78) are used in the 
formulation. In vitro studies have demonstrated that these molecules inhibit MDR by 
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inhibiting P-gp efflux pump. LN can easily be scaled up, even obtaining improved results 
over those produced in the laboratory.  
 
9. Expert opinion 
Nowadays, LN are widely being investigated in the field of pharmaceutical technology. 
LN formulations are based on traditional emulsion techniques and a broad spectrum of 
manufacturing methods are currently available. Production methods for LN have been 
widely modified since their invention by Speiser [14] in the 1980s. Most of these methods 
are based on the HPH and warm microemulsion technique developed respectively by 
Müller [17] and Gasco [19] in the 1990s. The investigations carried out in this field have 
led to improved nanoparticles due to the avoidance of degradation of thermolabile 
compounds, non-energy consuming methods, reproducibility, and low surfactant 
concentrations, among other factors. Most of them can be easily scaled up, HPH-based 
procedures being the most suitable for this purpose, as homogenizers have been used for a 
long time in the pharmaceutical industry. Indeed, LN produced on a large scale have been 
seen to present better size quality [29]. Regarding safety issues, LN present the advantage 
of being composed by GRAS lipids for oral, topical and intravenous administration. 
Therefore, LN matrix composition would not be potentially toxic unless large non-ionic 
surfactant or organic solvent quantities are used in the formulation. Several in vivo studies 
demonstrate that the intravenous administration of LN lower than 5 µm does not produce 
macroscopic toxicity [57, 58, 75, 110]. Besides, in vitro toxicity experiments have shown 
that LN do not affect Caco-2 cell viability [123], which makes this system suitable for oral 
administration. However, regardless of the potential safety of these nanosystems, further 
research is necessary in order to elucidate nanoparticle behavior after in vivo 
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administration, emphasizing the study of LN barrier crossing (e.g. intestinal barrier or 
BBB) and cell interaction. The knowledge of this basis would enable us to anticipate 
possible toxic effects.  
The antitumor activity of these nanosystems loaded with antitumor drugs has been widely 
demonstrated since their discovery. Studies carried out in the last five years show that 
antitumor drug toxicity is dramatically reduced when the drug is encapsulated into LN [63, 
92, 124]. Besides, LN provide higher bioavailability rates and prolonged plasma 
circulation times, thus improving drug efficacy [10, 58, 78, 125]. The advantages of LN 
over the administration of free drugs can be mainly explained by the passive and active 
targeting of the tumor tissue, mediated by the lipid vehicle. Another important 
improvement in these systems is that when some tensioactive molecules are used in the 
formulation, LN are able to overcome MDR [10, 62]. This benefit is due to the ability of 
LN to inhibit P-gp protein, which mediates the efflux of antitumor drugs from the cell and 
thus enhances intracellular drug concentration. Targeting anticancer drugs at the tumor 
avoids severe chemotherapy side effects. Although most studies in cancer treatment with 
LN are based on intravenous route, some authors have considered the oral route [9, 10], 
which is better tolerated in terms of patient welfare. These studies suggest that LN are 
absorbed via the lymphatic system after oral administration, achieving high drug 
concentration in lymph nodes. This fact might be very relevant in the avoidance of 
metastases and in lymphoma treatment. Bearing in mind the benefits of orally 
administrated LN, current research efforts should be focused on this route. Further studies 
are required in order to fully characterize their lymphatic absoption. Besides, intracellular 
uptake and interactions between cells and LN must be evaluated with the aim of clarifying 
the biodegradation, safety and toxicity aspects of these vehicles. Despite the need for 
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further research concerning these aspects of the field, and considering all the reviewed 
studies, in our opinion LN should provide more secure and effective antitumor treatments 
in the near future. 
 
Article highlights 
LN have been widely studied since their discovery in the 80’s. The broad spectrum of 
fabrication methods and targeting strategies have improved nanoparticles efficacy in 
tumor treatment.  
Their composition based on GRAS lipids for oral administration, guarantees less potential 
toxicity than other nanovehicles and their scaling-up is currently feasible.  
LN reduce drug toxicity and enhance antitumor activity mainly due to: a) passive and 
active targeting; and b) MDR overcoming (P-gp inhibition). 
Current investigations suggest two relevant advantages of LN in cancer treatment: a) the 
oral administration and further absorption through the lymphatic system; b) BBB 
penetration due to certain formulation components.  
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